Orum Therapeutics, Inc. is a biopharmaceutical company leveraging our proprietary platforms for research and development of new pharmaceuticals for cancer and immune diseases. We are pioneering a class of therapeutics intended to expand the universe of druggable targets and to meaningfully improve upon potency and tolerability, and thereby improve the therapeutic window of drugs.

Orum’s proprietary Dual-precision Targeted Protein Degradation (TPD² ™) approach uses antibodies to precisely deliver small molecule targeted protein degrader payloads to cancer cells and for other targeted biological therapies. The TPD² approach has produced our ORM-5029 and ORM-6151 product candidates and various early-stage technologies. TPD² is designed to merge the power of TPD with the precision of ADC technology, while overcoming the limitations of each modality. Whereas TPDs are typically small molecules that indiscriminately enter many cells throughout the body, we covalently attach protein degraders to antibodies to drive localization to specific cells. This is designed to improve upon what we believe are three critical limitations of conventional targeted protein degrader product candidates. Numerous diseases are instigated by proteins undergoing aberrant ubiquitination and subsequent degradation, and targeted stabilization of these proteins may lead to transformative therapeutics. Orum’s proprietary Dual-precision Targeted Protein Stabilization (TPS²) approach combines novel payloads with the precise cell delivery mechanism of antibodies to increase the levels of intracellular target proteins in a cell-type-specific manner for oncology and immuno-oncology. Leveraging the TPS² approach, we are enhancing anti-tumor immune response by directing Cbl-b inhibitors specifically to exhausted T cells via antibody delivery. By enabling the localization of Cbl-b inhibitors within the tumor microenvironment while simultaneously blocking the immune checkpoint signal, this dual-precision approach aims to broaden the horizon of cancer immunotherapies.

Private

Biotech